The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer
Open accessAbstract
PURPOSE: Fibroblast Activation Protein (FAP) is a tumor fibroblast protease that has been shown to potentiate colorectal cancer growth. The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer. METHODS: Patients with metastatic colorectal cancer who had previously received systemic chemotherapies were treated with single agent Val-boroPro 200 microg p.o. BID continuously. Eligibility included measurable disease, performance status of 0 to 2, and adequate organ function. Laboratory correlates evaluated the pharmacodynamic effects of Val-boroPro on FAP enzymatic function in the peripheral blood. RESULTS: Twenty-eight patients (median age 62; 12 males, 16 females) were enrolled in this study. There were no objective responses. Six of 28 (21%) patients had stable disease for a median of 25 weeks (range 11-38 weeks). Laboratory analysis demonstrated significant, although incomplete inhibition of FAP enzymatic activity in the peripheral blood. CONCLUSION: This phase II trial of Val-boroPro demonstrated minimal clinical activity in patients with previously treated metastatic colorectal cancer. However it provides the initial proof-of-concept that physiologic inhibition of FAP activity can be accomplished in patients with colorectal cancer, and lays the groundwork for future studies targeting the tumor stroma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Engvall, E., & Perlmann, P. (1972) · PubMed · Cited by 3,107
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Self-citationGarin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36505 · Cited by 586
Enzyme-linked Immunosorbent Assay, ELISA
ENGVALL, E., & PERLMANN, P. (1972) · Protides of the Biological Fluids · doi:10.1016/b978-0-08-016876-0.50102-x · Cited by 585
Scanlan, M. J., Raj, B. K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., & Rettig, W. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5657 · Cited by 574
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Engvall, E., Jonsson, K., & Perlmann, P. (1971) · Biochimica et Biophysica Acta (BBA) - Protein Structure · doi:10.1016/0005-2795(71)90132-2 · Cited by 443
Scott, A. M., Wiseman, G., Welt, S., Adjei, A. A., Lee, F.-T., Hopkins, W., Divgi, C. R., Hanson, L. J., Mitchell, P., Gansen, D. N., et al. (2003) · PubMed · Cited by 438
Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer
Henry, L. R., Lee, H.-O., Lee, J. S., Klein-Szanto, A., Watts, P., Ross, E. A., Chen, W.-T., & Cheng, J. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1746 · Cited by 364
Self-citationWelt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., & Old, L. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1193 · Cited by 266
Cheng, J. D., Dunbrack, R. L., Valianou, M., Rogatko, A., Alpaugh, R. K., & Weiner, L. M. (2002) · PubMed · Cited by 217
Self-citationAdams, S., Miller, G. T., Jesson, M. I., Watanabe, T., Jones, B., & Wallner, B. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0447 · Cited by 202
Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein
Lee, K. N., Jackson, K. W., Christiansen, V. J., Lee, C. S., Chun, J.-G., & McKee, P. A. (2006) · Blood · doi:10.1182/blood-2005-08-3452 · Cited by 190
Self-citationRettig, W. J., Garin‐Chesa, P., Healey, J. H., Su, S. L., Ozer, H. L., Schwab, M. G., Albino, A. P., & Old, L. J. (1993) · PubMed · Cited by 188
Chen, H. X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., Jaffe, C., Rubinstein, L., Zwiebel, J., & Kaplan, R. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1573 · Cited by 186
Piñeiro-Sánchez, M. L., Goldstein, L. A., Dodt, J., Howard, L., Yeh, Y., & Chen, W.-T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.7595 · Cited by 160
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth
Cheng, J. D., Valianou, M., Canutescu, A. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0269 · Cited by 129
Self-citationA novel plasma proteinase potentiates α2-antiplasmin inhibition of fibrin digestion
Lee, K. N., Jackson, K. W., Christiansen, V. J., Chung, K. H., & McKee, P. A. (2004) · Blood · doi:10.1182/blood-2003-12-4240 · Cited by 126
Self-citationRettig, W. J., Chesa, P. G., Beresford, H. R., Feickert, H. J., Jennings, M. T., Cohen, J., Oettgen, H. F., & Old, L. J. (1986) · PubMed · Cited by 116
Edosada, C. Y., Quan, C. L., Wiesmann, C., Tran, T., Sutherlin, D., Reynolds, M., Elliott, J. M., Raab, H. E., Fairbrother, W. J., & Wolf, B. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511112200 · Cited by 114
Edosada, C. Y., Quan, C. L., Tran, T., Pham, V. C., Wiesmann, C., Fairbrother, W. J., & Wolf, B. B. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.01.087 · Cited by 106
Ariga, N., Sato, E., Ohuchi, N., Nagura, H., & Ohtani, H. (2001) · International Journal of Cancer · Cited by 101
Iwasa, S., Okada, K., Chen, W., Jin, X., Yamane, T., Ooi, A., & Mitsumata, M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.06.030 · Cited by 97
Cheng, J. D., & Weiner, L. M. (2003) · PubMed · Cited by 68
Self-citationThe effect of a single nucleotide polymorphism on human α2-antiplasmin activity
Christiansen, V. J., Jackson, K. W., Lee, K. N., & McKee, P. A. (2007) · Blood · doi:10.1182/blood-2007-01-065185 · Cited by 40
Self-citation
Cited by
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Qi, J., Sun, H., Zhang, Y., Wang, Z., Xun, Z., Li, Z., Ding, X., Bao, R., Hong, L., Jia, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29366-6 · Cited by 952
In search of definitions: Cancer‐associated fibroblasts and their markers
Nurmik, M., Ullmann, P., Rodriguez, F., Haan, S., & Letellier, E. (2020) · International Journal of Cancer · doi:10.1002/ijc.32193 · Cited by 739
Fibroblasts in cancer: Unity in heterogeneity
Chhabra, Y., & Weeraratna, A. T. (2023) · Cell · doi:10.1016/j.cell.2023.03.016 · Cited by 474
Metadata
- Authors
- Narra, K., Mullins, S. R., Lee, H.-O., Strzemkowski-Brun, B., Magalong, K., Christiansen, V. J., McKee, P. A., Egleston, B., Cohen, S. J., Weiner, L. M., Meropol, N. J., & Cheng, J. D.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 1691-1699
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2015616022
- Cited by
- 275
- References
- 38
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.